Neuromyelitis Optica Spectrum Disorder Market Set for Significant Growth by 2036, Driven by Expanding Patient Pool, Advanced Diagnostics, and Emerging Therapies | DelveInsight

DelveInsight’s report, “Neuromyelitis Optica Spectrum Disorder Market Insight, Epidemiology, and Market Forecast–2036,” provides a comprehensive analysis of the Neuromyelitis Optica Spectrum Disorder landscape. The report delivers detailed insights into the disease, including historical and forecasted epidemiology, helping stakeholders understand diagnosed prevalence, patient burden, and market opportunities across key regions.

Additionally, it examines Neuromyelitis Optica Spectrum Disorder market dynamics, offering a thorough assessment of current treatment practices, unmet needs, and emerging therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and commercialization initiatives.

To know in detail about the Neuromyelitis Optica Spectrum Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

Key Takeaways from the Neuromyelitis Optica Spectrum Disorder Market Report

• The Neuromyelitis Optica Spectrum Disorder market size in the 7MM is projected to increase significantly by 2036, mainly due to rising diagnosed cases, better awareness, and continued therapeutic advancements.

• The United States accounted for the highest market size among the 7MM in 2025.

• According to the NICE UK, the diagnosed prevalence rate of NMOSD is estimated at nearly 1.5 per 100,000 population. Between 70–80% of NMOSD patients will have anti-AQP4 antibodies.

• Leading companies advancing the pipeline include Bio-Thera Solutions and RemeGen/Vor Bio, with promising candidates such as BAT4406F and Telitacicept (RC18).

• BAT4406F is in Phase II development and demonstrated superiority versus the control arm in a China trial.

• Telitacicept (RC18) is being developed as a novel fusion protein targeting BLyS and APRIL pathways involved in B-cell activation.

Key Factors Driving the Neuromyelitis Optica Spectrum Disorder Market

Rising Awareness and Earlier Diagnosis Rates: Increasing awareness of autoimmune neurological diseases, along with broader access to MRI and antibody testing, is enabling earlier and more accurate diagnosis. Improved recognition among healthcare professionals and patients is expected to expand the identified treatment-eligible population.

High Unmet Need Driving Innovative Therapies: Despite approved therapies, long-term disease control and relapse prevention remain challenges. This creates strong opportunities for novel targeted treatments with improved efficacy, safety, and convenience.

Regulatory Support Accelerating Pipeline Development: Supportive regulatory pathways and increasing rare disease focus are encouraging research and development activities, accelerating clinical advancement and commercialization opportunities.

Severe Disease Burden Supporting Premium Pricing Potential: The disabling nature of NMOSD, risk of blindness, paralysis, and repeated relapses support premium pricing opportunities for effective therapies offering durable protection.

Neuromyelitis Optica Spectrum Disorder Market Analysis

The current approach to managing Neuromyelitis Optica Spectrum Disorder involves effective treatments but no cure. Acute attacks are usually treated with high-dose intravenous corticosteroids like methylprednisolone. For severe acute attacks unresponsive to corticosteroids, plasma exchange may be effective.

Chronic immunosuppressive therapy can be accomplished with azathioprine or rituximab as first-line agents. Second-line agents may include mycophenolate or methotrexate. Newer biologics are directed against specific immune mediators such as anti-IL-6, anti-complement, or anti-AQP4-IgG.

Some of the US FDA-approved drugs for the treatment of NMOSD include ENSPRYNG (Genentech), ULTOMIRIS (AstraZeneca), SOLIRIS (Alexion/AstraZeneca), and others.

Get a Free sample for the Neuromyelitis Optica Spectrum Disorder Market Forecast, Size & Share Analysis Report: Neuromyelitis Optica Spectrum Disorder Market Forecast

Neuromyelitis Optica Spectrum Disorder Competitive Landscape

Key companies such as Bio-Thera Solutions and RemeGen/Vor Bio are leading the pipeline with differentiated approaches that could transform future treatment options and create meaningful commercial opportunities.

BAT4406F (Bio-Thera Solutions): Investigational Phase II glyco-engineered monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity. It is a type I anti-CD20 antibody being evaluated for autoimmune indications, including NMOSD. In July 2025, the China NMOSD clinical trial was terminated early after meeting predefined superiority criteria versus the control arm.

Telitacicept (RC18) (RemeGen/Vor Bio): Proprietary novel fusion protein designed to treat autoimmune diseases by targeting BLyS and APRIL signaling molecules involved in B-cell development. In June 2025, VOR BIO obtained rights to develop and commercialize telitacicept outside Greater China.

Discover more about therapies set to grab major Neuromyelitis Optica Spectrum Disorder market share @ Neuromyelitis Optica Spectrum Disorder Treatment Landscape

Recent Development in the Neuromyelitis Optica Spectrum Disorder Treatment Landscape:

• In July 2025, the BAT4406F NMOSD clinical trial in China was terminated early after meeting superiority criteria versus the control arm.

• In January 2025, Phase I data showed BAT4406F was well tolerated with sustained depletion of CD19-positive B cells.

• In June 2025, VOR BIO entered into an exclusive global licensing agreement with REMEGEN for telitacicept.

• In July 2025, NHS England recommended and funded ACTEMRA (tocilizumab) for refractory or intolerant NMOSD patients.

What is Neuromyelitis Optica Spectrum Disorder?

Neuromyelitis Optica Spectrum Disorder (NMOSD), also referred to as Devic's disease, is a long-term autoimmune condition affecting the brain and spinal cord. NMOSD primarily targets the optic nerves, brainstem, and spinal cord. Symptoms may include vision loss, paralysis, sensory impairment, and recurrent inflammatory attacks.

NMOSD is regarded as an autoimmune disease though the exact cause of the autoimmunity is unknown. AQP4-IgG blood testing is highly specific and moderately sensitive for diagnosis.

Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation:

The Neuromyelitis Optica Spectrum Disorder market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalent Cases of Neuromyelitis Optica Spectrum Disorder

• Total Diagnosed Prevalent Cases of Neuromyelitis Optica Spectrum Disorder

• Gender-specific Diagnosed Prevalent Cases of Neuromyelitis Optica Spectrum Disorder

• Treated Cases of Neuromyelitis Optica Spectrum Disorder

• Diagnosed Prevalent Cases in the US

• Diagnosed Prevalent Cases in EU4 and the UK

• Diagnosed Prevalent Cases in Japan

Download the report to understand which factors are driving Neuromyelitis Optica Spectrum Disorder epidemiology trends @ Neuromyelitis Optica Spectrum Disorder Epidemiology Forecast

Scope of the Neuromyelitis Optica Spectrum Disorder Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Companies: Bio-Thera Solutions, RemeGen/Vor Bio, and others

• Key Therapies: BAT4406F, Telitacicept (RC18), and others

• Market Dynamics: Drivers and Barriers

• Competitive Intelligence Analysis: SWOT, market entry strategies, reimbursement scenario

• Unmet Needs, KOL Views, Analyst Views, Market Access and Reimbursement

Table of Contents

1. Neuromyelitis Optica Spectrum Disorder Market Report Introduction

2. Executive Summary for Neuromyelitis Optica Spectrum Disorder

3. SWOT Analysis of Neuromyelitis Optica Spectrum Disorder

4. Neuromyelitis Optica Spectrum Disorder Patient Share (%) Overview at a Glance

5. Neuromyelitis Optica Spectrum Disorder Market Overview at a Glance

6. Neuromyelitis Optica Spectrum Disorder Background and Overview

7. Neuromyelitis Optica Spectrum Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuromyelitis Optica Spectrum Disorder

9. Neuromyelitis Optica Spectrum Disorder Current Treatment and Medical Practices

10. Neuromyelitis Optica Spectrum Disorder Unmet Needs

11. Neuromyelitis Optica Spectrum Disorder Emerging Therapies

12. Neuromyelitis Optica Spectrum Disorder Market Outlook

13. Country-Wise Neuromyelitis Optica Spectrum Disorder Market Analysis (2022–2036)

14. Neuromyelitis Optica Spectrum Disorder Market Access and Reimbursement of Therapies

15. Neuromyelitis Optica Spectrum Disorder Market Drivers

16. Neuromyelitis Optica Spectrum Disorder Market Barriers

17. Neuromyelitis Optica Spectrum Disorder Appendix

18. Neuromyelitis Optica Spectrum Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Neuromyelitis Optica Spectrum Disorder Market Set for Significant Growth by 2036, Driven by Expanding Patient Pool, Advanced Diagnostics, and Emerging Therapies | DelveInsight